Combined with in vivo experimental validation, it was revealed that the mechanism by which ZSQYJDF treats EMs is likely closely related to the activation of the NRF2/HO1 signaling pathway. The gene discussed is NFE2L2; the disease is eosinophilia-myalgia syndrome.